The Journal of Physical Chemistry C, ISSN 1932-7447, 01/2010, Volume 114, Issue 2, pp. 1337 - 1342
The Y-α-SiAlON fine powders have been successfully synthesized from the system Y2O3−Al2O3−SiO2, by using the gas-reduction−nitridation method. Completion of...
C: Electron Transport, Optical and Electronic Devices, Hard Matter | EU PHOSPHORS | THERMAL-EXPANSION | CARBOTHERMAL REDUCTION | CRYSTAL-STRUCTURE | MATERIALS SCIENCE, MULTIDISCIPLINARY | REDUCTION-NITRIDATION METHOD | OPTICAL-PROPERTIES | CHEMISTRY, PHYSICAL | LUMINESCENCE PROPERTIES | NANOSCIENCE & NANOTECHNOLOGY | HIGH-TEMPERATURE SYNTHESIS | CERAMICS
C: Electron Transport, Optical and Electronic Devices, Hard Matter | EU PHOSPHORS | THERMAL-EXPANSION | CARBOTHERMAL REDUCTION | CRYSTAL-STRUCTURE | MATERIALS SCIENCE, MULTIDISCIPLINARY | REDUCTION-NITRIDATION METHOD | OPTICAL-PROPERTIES | CHEMISTRY, PHYSICAL | LUMINESCENCE PROPERTIES | NANOSCIENCE & NANOTECHNOLOGY | HIGH-TEMPERATURE SYNTHESIS | CERAMICS
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 14, pp. 1319 - 1330
In patients with stable cardiovascular disease, those receiving rivaroxaban plus aspirin had fewer major cardiovascular events but more major bleeding events...
TRIAL | MEDICINE, GENERAL & INTERNAL | RISK | ORAL RIVAROXABAN | CLOPIDOGREL | SECONDARY PREVENTION | Atherosclerosis - drug therapy | Double-Blind Method | Cardiovascular Diseases - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Atherosclerosis - complications | Male | Secondary Prevention - methods | Factor Xa Inhibitors - therapeutic use | Rivaroxaban - adverse effects | Aspirin - adverse effects | Factor Xa Inhibitors - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Aspirin - therapeutic use | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Rivaroxaban | Aspirin | Patient outcomes | Outcome and process assessment (Health Care) | Reports | Dosage and administration | Research | Cardiovascular diseases | Drug therapy | Observations | Methods | Myocardial infarction | Cerebral infarction | Medical research | Cardiovascular disease | Bleeding | Studies | Disease prevention | Arteriosclerosis | Coronary vessels | Atherosclerosis | Drug dosages | Life Sciences | Human health and pathology
TRIAL | MEDICINE, GENERAL & INTERNAL | RISK | ORAL RIVAROXABAN | CLOPIDOGREL | SECONDARY PREVENTION | Atherosclerosis - drug therapy | Double-Blind Method | Cardiovascular Diseases - drug therapy | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Atherosclerosis - complications | Male | Secondary Prevention - methods | Factor Xa Inhibitors - therapeutic use | Rivaroxaban - adverse effects | Aspirin - adverse effects | Factor Xa Inhibitors - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Aspirin - therapeutic use | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Rivaroxaban - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Rivaroxaban | Aspirin | Patient outcomes | Outcome and process assessment (Health Care) | Reports | Dosage and administration | Research | Cardiovascular diseases | Drug therapy | Observations | Methods | Myocardial infarction | Cerebral infarction | Medical research | Cardiovascular disease | Bleeding | Studies | Disease prevention | Arteriosclerosis | Coronary vessels | Atherosclerosis | Drug dosages | Life Sciences | Human health and pathology
Journal Article
CANCER RESEARCH, ISSN 0008-5472, 04/2009, Volume 69, Issue 7, pp. 3148 - 3156
Programmed cell death protein 4 (PDCD4) has recently been shown to be involved in both transcription and translation, and to regulate cell growth. However, the...
TRANSCRIPTION FACTORS | HEPATOCELLULAR-CARCINOMA | INVASION | ONCOLOGY | GENE-EXPRESSION | PDCD4 | CISPLATIN RESISTANCE | TRANSFORMATION SUPPRESSOR | DRUG-RESISTANCE | TRANSLATION | UP-REGULATION | Prostatic Neoplasms - metabolism | RNA-Binding Proteins - genetics | Paclitaxel - pharmacology | Humans | Cell Growth Processes - physiology | Male | Glioma - metabolism | Glioma - genetics | RNA-Binding Proteins - biosynthesis | Prostatic Neoplasms - genetics | Transfection | Glioma - pathology | Apoptosis Regulatory Proteins - genetics | Transcription, Genetic | Y-Box-Binding Protein 1 - genetics | Nuclear Proteins - genetics | Prostatic Neoplasms - drug therapy | Apoptosis Regulatory Proteins - biosynthesis | Prostatic Neoplasms - pathology | Twist-Related Protein 1 - antagonists & inhibitors | Down-Regulation | Nuclear Proteins - metabolism | Cisplatin - pharmacology | Apoptosis Regulatory Proteins - metabolism | Nuclear Proteins - antagonists & inhibitors | Twist-Related Protein 1 - genetics | Cell Line, Tumor | Twist-Related Protein 1 - metabolism | Glioma - drug therapy | RNA-Binding Proteins - metabolism | Y-Box-Binding Protein 1 - biosynthesis
TRANSCRIPTION FACTORS | HEPATOCELLULAR-CARCINOMA | INVASION | ONCOLOGY | GENE-EXPRESSION | PDCD4 | CISPLATIN RESISTANCE | TRANSFORMATION SUPPRESSOR | DRUG-RESISTANCE | TRANSLATION | UP-REGULATION | Prostatic Neoplasms - metabolism | RNA-Binding Proteins - genetics | Paclitaxel - pharmacology | Humans | Cell Growth Processes - physiology | Male | Glioma - metabolism | Glioma - genetics | RNA-Binding Proteins - biosynthesis | Prostatic Neoplasms - genetics | Transfection | Glioma - pathology | Apoptosis Regulatory Proteins - genetics | Transcription, Genetic | Y-Box-Binding Protein 1 - genetics | Nuclear Proteins - genetics | Prostatic Neoplasms - drug therapy | Apoptosis Regulatory Proteins - biosynthesis | Prostatic Neoplasms - pathology | Twist-Related Protein 1 - antagonists & inhibitors | Down-Regulation | Nuclear Proteins - metabolism | Cisplatin - pharmacology | Apoptosis Regulatory Proteins - metabolism | Nuclear Proteins - antagonists & inhibitors | Twist-Related Protein 1 - genetics | Cell Line, Tumor | Twist-Related Protein 1 - metabolism | Glioma - drug therapy | RNA-Binding Proteins - metabolism | Y-Box-Binding Protein 1 - biosynthesis
Journal Article